Carmen González-Yanes

Carmen González-Yanes

Auto-generated profile, based on publicly available information

Carmen González-Yanes

Department of Clinical Biochemistry

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2013 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
JCJuan R. Calvo
Juan R. Calvo
CGC. González‐Yanes
C. González‐Yanes
MMM.D. Maldonado
M.D. Maldonado

23 March 2010 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
PFPatricia Fernández-Riejos
Patricia Fernández-Riejos
SNSouad Najib
Souad Najib
JSJose Santos-Alvarez
Jose Santos-Alvarez
CMConsuelo Martín-Romero
Consuelo Martín-Romero
APAntonio Pérez-Pérez
Antonio Pérez-Pérez
VSVíctor Sánchez-Margalet
Víctor Sánchez-Margalet
Adipose tissue is an active endocrine organ that secretes various humoral factors (adipokines), and its shift to production of proinflammatory cytokines in obesity likely contributes to the low-level systemic inflammation that may be present in metabolic syndrome-associated chronic pathologies such as atherosclerosis. Leptin is one of the most important hormones secreted by adipocytes, with a variety of physiological roles related to the control of metabolism and energy homeostasis. One of these functions is the connection between nutritional status and immune competence. The adipocyte-derived hormone leptin has been shown to regulate the immune response, innate and adaptive response, both in normal and pathological conditions. The role of leptin in regulating immune response has been assessed in vitro as well as in clinical studies. It has been shown that conditions of reduced leptin production are associated with increased infection susceptibility. Conversely, immune-mediated disorders such as autoimmune diseases are associated with increased secretion of leptin and production of proinflammatory pathogenic cytokines. Thus, leptin is a mediator of the inflammatory response.

24 June 2003 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
VSVíctor Sánchez-Margalet
Víctor Sánchez-Margalet
CMC. Martín‐Romero
C. Martín‐Romero
JSJ. Santos‐Alvarez
J. Santos‐Alvarez
RGR. Goberna
R. Goberna
SNSouad Najib
Souad Najib
CGC. Gonzalez‐Yanes
C. Gonzalez‐Yanes

1 September 2005 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
DODaniel T. O’connor
Daniel T. O’connor
PCPeter E. Cadman
Peter E. Cadman
CSClayton Smiley
Clayton Smiley
RSRany M. Salem
Rany M. Salem
FRFangwen Rao
Fangwen Rao
VSVíctor Sánchez-Margalet
Víctor Sánchez-Margalet
The chromogranin A (CHGA) fragment pancreastatin (human CHGA250-301) impairs glucose metabolism, but the role of human pancreastatin in vivo remains unexplored. We studied brachial arterial infusion of pancreastatin (CHGA273-301-amide at approximately 200 nm) on forearm metabolism of glucose, free fatty acids, and amino acids. Plasma pancreastatin was measured in obesity or type 2 diabetes. Systematic discovery of amino acid variation was performed, and the potency of one variant in the active carboxyl terminus (Gly297Ser) was tested. Pancreastatin decreased glucose uptake by approximately 48-50%; the lack of change in forearm plasma flow indicated a metabolic, rather than hemodynamic, mechanism. A control CHGA peptide (catestatin, CHGA352-372) did not affect glucose. Insulin increased glucose uptake, but pancreastatin did not antagonize this action. Pancreastatin increased spillover of free fatty acids by about 4.5- to 6.4-fold, but not spillover of amino acids. Insulin diminished spillover of both free fatty acids and amino acids, but these actions were not reversed by pancreastatin. Plasma pancreastatin was elevated approximately 3.7-fold in diabetes, but was unchanged during weight loss. Proteolytic cleavage sites for pancreastatin in vivo were documented by matrix-assisted laser desorption ionization/time of flight mass spectrometry. Three pancreastatin variants were discovered: Arg253Trp, Ala256Gly, and Gly297Ser. The Gly297Ser variant had unexpectedly increased potency to inhibit glucose uptake. The dysglycemic peptide pancreastatin is specifically and potently active in humans on multiple facets of intermediary metabolism, although it did not antagonize insulin. Pancreastatin is elevated in diabetes, and the variant Gly297Ser had increased potency to inhibit glucose uptake. The importance of human pancreastatin in vivo as well as its natural variants is established.

1 January 2005 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
SNSouad Najib
Souad Najib
CMC. Martín-Romero
C. Martín-Romero
CGC. González-Yanes
C. González-Yanes
VSVíctor Sánchez-Margalet
Víctor Sánchez-Margalet

28 June 2002 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
VSVíctor Sánchez-Margalet
Víctor Sánchez-Margalet
CMC. Martín-Romero
C. Martín-Romero
CGC. González-Yanes
C. González-Yanes
RGR. Goberna
R. Goberna
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
MMM A Muniain
M A Muniain
SUMMARY: Leptin, the Ob gene product, is an adipocyte hormone that centrally regulates weight control. In addition, other effects of leptin in peripheral tissues have been described. Thus, leptin has been found to regulate reproduction, haematopoiesis and immune function. We have found recently that leptin has a stimulatory effect on human peripheral blood mononuclear cells (PBMC). Monocytes are activated by leptin alone whereas T lymphocytes need a suboptimal stimulus of PHA or ConA before further activation by leptin. These effects are mediated by the long isoform of the leptin receptor, which has been shown to trigger signalling in PBMC. In fact, we have found that human leptin stimulates Janus kinase (JAK)-signal transducer and activator of transcription (STAT), phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways in PBMC. In order to assess possible regulation of the long isoform of the leptin receptor (Ob-R) in mononuclear cells upon activation, we have studied the expression of Ob-R by RT-PCR and Western blotting in PBMC activated in vitro by PHA or ConA and in vivo in HIV-infected patients. We have found that in vitro activation and in vivo HIV infection correlates with an increase in leptin receptor expression in PBMC. Moreover, the leptin receptor is tyrosine phosphorylated in PBMC from HIV-infected patients, suggesting that the leptin receptor is activated. These results are consistent with the suggested role of leptin in modulating the immune response.